731 related articles for article (PubMed ID: 24259734)
1. Gaucher disease and its treatment options.
Bennett LL; Mohan D
Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
[TBL] [Abstract][Full Text] [Related]
2. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.
Bennett LL; Turcotte K
Drug Des Devel Ther; 2015; 9():4639-47. PubMed ID: 26345314
[TBL] [Abstract][Full Text] [Related]
3. Gaucher's disease: a review.
Morales LE
Ann Pharmacother; 1996 Apr; 30(4):381-8. PubMed ID: 8729893
[TBL] [Abstract][Full Text] [Related]
4. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
5. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology.
Grabowski GA; Golembo M; Shaaltiel Y
Mol Genet Metab; 2014 May; 112(1):1-8. PubMed ID: 24630271
[TBL] [Abstract][Full Text] [Related]
6. Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States.
Nalysnyk L; Sugarman R; Cele C; Uyei J; Ward A
J Manag Care Spec Pharm; 2018 Oct; 24(10):1002-1008. PubMed ID: 30247105
[TBL] [Abstract][Full Text] [Related]
7. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
[TBL] [Abstract][Full Text] [Related]
8. A Brazilian Rare-Disease Center's Experience with Glucosylsphingosine (lyso-Gb1) in Patients with Gaucher Disease: Exploring a Novel Correlation with IgG Levels in Plasma and a Biomarker Measurement in CSF.
Vernet Machado Bressan Wilke M; Iop GD; Faqueti L; Lemos da Silva LA; Kubaski F; Poswar FO; Michelin-Tirelli K; Randon D; Borelli WV; Giugliani R; Schwartz IVD
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474117
[TBL] [Abstract][Full Text] [Related]
9. Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases.
Cox TM
Curr Opin Investig Drugs; 2010 Oct; 11(10):1169-81. PubMed ID: 20872320
[TBL] [Abstract][Full Text] [Related]
10. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease.
Moyses C
Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):955-60. PubMed ID: 12803929
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review and Meta-analyses of Longitudinal Studies on Drug Treatments for Gaucher Disease.
Leonart LP; Fachi MM; Böger B; Silva MRD; Szpak R; Lombardi NF; Pedroso MLA; Pontarolo R
Ann Pharmacother; 2023 Mar; 57(3):267-282. PubMed ID: 35815393
[TBL] [Abstract][Full Text] [Related]
12. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
Pastores GM
Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
[TBL] [Abstract][Full Text] [Related]
13. Management of Gaucher disease: enzyme replacement therapy.
Zimran A; Elstein D
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():82-7. PubMed ID: 25345089
[TBL] [Abstract][Full Text] [Related]
14. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.
Belmatoug N; Di Rocco M; Fraga C; Giraldo P; Hughes D; Lukina E; Maison-Blanche P; Merkel M; Niederau C; Plӧckinger U; Richter J; Stulnig TM; Vom Dahl S; Cox TM
Eur J Intern Med; 2017 Jan; 37():25-32. PubMed ID: 27522145
[TBL] [Abstract][Full Text] [Related]
15. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
16. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.
van Dussen L; Hendriks EJ; Groener JE; Boot RG; Hollak CE; Aerts JM
J Inherit Metab Dis; 2014 Nov; 37(6):991-1001. PubMed ID: 24831585
[TBL] [Abstract][Full Text] [Related]
17. Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat.
Mikosch P; Reed M; Baker R; Holloway B; Berger L; Mehta AB; Hughes DA
Calcif Tissue Int; 2008 Jul; 83(1):43-54. PubMed ID: 18553043
[TBL] [Abstract][Full Text] [Related]
18. [Molecular basis of treatment in Gaucher's disease].
Pocoví M
Med Clin (Barc); 2011 Sep; 137 Suppl 1():32-8. PubMed ID: 22230123
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States.
Balwani M; Burrow TA; Charrow J; Goker-Alpan O; Kaplan P; Kishnani PS; Mistry P; Ruskin J; Weinreb N
Mol Genet Metab; 2016 Feb; 117(2):95-103. PubMed ID: 26387627
[TBL] [Abstract][Full Text] [Related]
20. Gaucher's disease in Lithuania: its diagnosis and treatment.
Kleinotienė G; Tylki-Szymanska A; Czartoryska B
Medicina (Kaunas); 2011; 47(7):405-11. PubMed ID: 22112991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]